Published in Adv Drug Deliv Rev on April 25, 2001
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. Proc Natl Acad Sci U S A (2005) 1.41
Lipoprotein-inspired nanoparticles for cancer theranostics. Acc Chem Res (2011) 1.30
Molecular structure of low density lipoprotein: current status and future challenges. Eur Biophys J (2008) 1.17
Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging (2014) 1.11
The role of cholesterol metabolism and cholesterol transport in carcinogenesis: a review of scientific findings, relevant to future cancer therapeutics. Front Pharmacol (2013) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
Harnessing a physiologic mechanism for siRNA delivery with mimetic lipoprotein particles. Mol Ther (2012) 1.04
A tissue-engineered model of the intestinal lacteal for evaluating lipid transport by lymphatics. Biotechnol Bioeng (2009) 0.96
HDL as a contrast agent for medical imaging. Clin Lipidol (2009) 0.92
Naphthalocyanine-reconstituted LDL nanoparticles for in vivo cancer imaging and treatment. Int J Nanomedicine (2007) 0.90
High-Density Lipoproteins: Nature's Multifunctional Nanoparticles. ACS Nano (2016) 0.87
Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers. Nanomedicine (Lond) (2012) 0.87
High-density lipoprotein as a potential carrier for delivery of a lipophilic antitumoral drug into hepatoma cells. World J Gastroenterol (2005) 0.87
Mammaglobin as a potential molecular target for breast cancer drug delivery. Cancer Cell Int (2009) 0.84
Chitosan enhances the stability and targeting of immuno-nanovehicles to cerebro-vascular deposits of Alzheimer's disease amyloid protein. Nanomedicine (2011) 0.84
Isolation, characterization, and stability of discretely-sized nanolipoprotein particles assembled with apolipophorin-III. PLoS One (2010) 0.83
Lipoproteins and lipoprotein mimetics for imaging and drug delivery. Adv Drug Deliv Rev (2016) 0.81
Equilibrium and kinetic studies of the interactions of a porphyrin with low-density lipoproteins. Biophys J (2002) 0.81
Evaluation of nanolipoprotein particles (NLPs) as an in vivo delivery platform. PLoS One (2014) 0.81
Learning from biology: synthetic lipoproteins for drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2014) 0.80
Ganglioside embedded in reconstituted lipoprotein binds cholera toxin with elevated affinity. J Lipid Res (2010) 0.80
Stoichiometry of reconstituted high-density lipoproteins in the hydrated state determined by photon antibunching. Biophys J (2011) 0.79
Low density lipoprotein bionanoparticles: From cholesterol transport to delivery of anti-cancer drugs. Saudi Pharm J (2013) 0.78
Recombinant high-density lipoprotein nanoparticles containing gadolinium-labeled cholesterol for morphologic and functional magnetic resonance imaging of the liver. Int J Nanomedicine (2012) 0.78
Recent Progress in Light-Triggered Nanotheranostics for Cancer Treatment. Theranostics (2016) 0.77
Circulating Lipoproteins: A Trojan Horse Guiding Squalenoylated Drugs to LDL-Accumulating Cancer Cells. Mol Ther (2017) 0.77
Lipoproteins: When size really matters. Curr Opin Colloid Interface Sci (2006) 0.75
Low Density Lipid Nanoparticles for Solid Tumor Targeting. Sci Pharm (2014) 0.75
Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging. Curr Med Chem (2015) 0.75
B lymphocyte receptors and polyphosphoinositide degradation. Cell (1985) 2.66
In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells. J Biol Chem (1983) 2.61
The influence of cytokines on the integrity of the blood-brain barrier in vitro. J Neuroimmunol (1996) 2.34
Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ Res (2001) 1.91
Selective liver targeting of antivirals by recombinant chylomicrons--a new therapeutic approach to hepatitis B. Nat Med (1995) 1.77
Induction of rapid atherogenesis by perivascular carotid collar placement in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Circulation (2001) 1.77
The blood-brain barrier in neuroinflammatory diseases. Pharmacol Rev (1997) 1.73
Vascular adhesion molecule-1 and intercellular adhesion molecule-1 expression on rat liver cells after lipopolysaccharide administration in vivo. Hepatology (1995) 1.69
5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. Pharm Res (1998) 1.66
The impact and recovery of asteroid 2008 TC(3). Nature (2009) 1.60
Apolipoprotein E protects against bacterial lipopolysaccharide-induced lethality. A new therapeutic approach to treat gram-negative sepsis. J Biol Chem (2001) 1.59
Crosslinking of surface immunoglobulin and Fc receptors on B lymphocytes inhibits stimulation of inositol phospholipid breakdown via the antigen receptors. J Exp Med (1985) 1.51
Structural characterisation of the exopolysaccharide produced by Lactobacillus delbrückii subspecies bulgaricus rr grown in skimmed milk. Carbohydr Res (1993) 1.49
Cross-linking of surface immunoglobulin on B lymphocytes induces both intracellular Ca2+ release and Ca2+ influx: analysis with indo-1. Biochem Biophys Res Commun (1986) 1.44
Apolipoprotein C-III deficiency accelerates triglyceride hydrolysis by lipoprotein lipase in wild-type and apoE knockout mice. J Lipid Res (2001) 1.43
Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation (2006) 1.41
Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun (2009) 1.36
Receptor signalling and crosstalk in B lymphocytes. Immunol Rev (1987) 1.33
Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J (2001) 1.31
Determination of the upper size limit for uptake and processing of ligands by the asialoglycoprotein receptor on hepatocytes in vitro and in vivo. J Biol Chem (2001) 1.30
In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res (1997) 1.28
Particle size determines the specificity of apolipoprotein E-containing triglyceride-rich emulsions for the LDL receptor versus hepatic remnant receptor in vivo. J Lipid Res (1997) 1.24
Tissue distribution of factor VIII gene expression in vivo--a closer look. Thromb Haemost (2001) 1.24
Endotoxin induction of plasminogen activator and plasminogen activator inhibitor type 1 mRNA in rat tissues in vivo. J Biol Chem (1990) 1.24
Fibrin and activated platelets cooperatively guide stem cells to a vascular injury and promote differentiation towards an endothelial cell phenotype. Arterioscler Thromb Vasc Biol (2006) 1.22
Hormonal control of glycogenolysis in parenchymal liver cells by Kupffer and endothelial liver cells. J Biol Chem (1988) 1.21
FcalphaRI-positive liver Kupffer cells: reappraisal of the function of immunoglobulin A in immunity. Nat Med (2000) 1.19
Low density lipoprotein receptor internalizes low density and very low density lipoproteins that are bound to heparan sulfate proteoglycans via lipoprotein lipase. J Biol Chem (1993) 1.19
Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo. J Clin Invest (1997) 1.18
Structure of the exopolysaccharide produced by Lactococcus lactis subspecies cremoris H414 grown in a defined medium or skimmed milk. Carbohydr Res (1992) 1.17
Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells. J Biol Chem (1988) 1.12
Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem (1996) 1.11
Selective uptake of cholesteryl esters from apolipoprotein-E-free high-density lipoproteins by rat parenchymal cells in vivo is efficiently coupled to bile acid synthesis. Biochem J (1991) 1.09
Scavenger receptors on liver Kupffer cells mediate the in vivo uptake of oxidatively damaged red blood cells in mice. Blood (2000) 1.09
Activation and proliferation signals in mouse B cells. VIII. Induction of DNA synthesis in B cells by a combination of calcium ionophores and phorbol myristate acetate. Eur J Immunol (1986) 1.09
Fate and effects of 4-chlorophenol and 2,4-dichlorophenol in marine plankton communities in experimental enclosures. Ecotoxicol Environ Saf (1984) 1.08
In vivo regulation of scavenger receptor BI and the selective uptake of high density lipoprotein cholesteryl esters in rat liver parenchymal and Kupffer cells. J Biol Chem (1998) 1.08
Overexpression of IL-18 decreases intimal collagen content and promotes a vulnerable plaque phenotype in apolipoprotein-E-deficient mice. Arterioscler Thromb Vasc Biol (2004) 1.07
Hepatic and extrahepatic scavenger receptors: function in relation to disease. Arterioscler Thromb Vasc Biol (2000) 1.06
Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation (2005) 1.06
Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler Thromb Vasc Biol (2007) 1.05
The multiple roles of macrophage scavenger receptors (MSR) in vivo: resistance to atherosclerosis and susceptibility to infection in MSR knockout mice. J Atheroscler Thromb (1997) 1.04
Endotoxin stimulates glycogenolysis in the liver by means of intercellular communication. J Biol Chem (1988) 1.04
Association of antisense oligonucleotides with lipoproteins prolongs the plasma half-life and modifies the tissue distribution. Nucleic Acids Res (1991) 1.03
Effect of endotoxin on permeability of bovine cerebral endothelial cell layers in vitro. J Pharmacol Exp Ther (1996) 1.03
Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo. J Biol Chem (1996) 1.02
Local atherosclerotic plaques are a source of prognostic biomarkers for adverse cardiovascular events. Arterioscler Thromb Vasc Biol (2009) 1.02
Eicosanoid production by rat cerebral endothelial cells: stimulation by lipopolysaccharide, interleukin-1 and interleukin-6. J Neuroimmunol (1995) 1.01
Receptor-mediated endocytosis of tissue-type plasminogen activator (t-PA) by liver cells. Thromb Res Suppl (1990) 1.01
Heparan sulphate proteoglycans are involved in the lipoprotein lipase-mediated enhancement of the cellular binding of very low density and low density lipoproteins. Biochem Biophys Res Commun (1992) 1.01
Conditioned media of Kupffer and endothelial liver cells influence protein phosphorylation in parenchymal liver cells. Involvement of prostaglandins. Biochem J (1988) 1.00
Differential effects of regulatory T cells on the initiation and regression of atherosclerosis. Atherosclerosis (2011) 0.99
Lactoferrin uptake by the rat liver. Characterization of the recognition site and effect of selective modification of arginine residues. J Biol Chem (1992) 0.99
Hepatic processing of the cholesteryl ester from low density lipoprotein in the rat. J Biol Chem (1986) 0.99
Scavenger receptor BI mediates the selective uptake of oxidized cholesterol esters by rat liver. J Biol Chem (1999) 0.99
Hormone-induced changes in pyruvate kinase. Effects of glucagon and starvation. Eur J Biochem (1977) 0.99
The effect of Ca2+ and the trifluoperazine on the processing of human acetylated low density lipoprotein by non-parenchymal liver cells. FEBS Lett (1981) 0.99
Synthesis of cluster galactosides with high affinity for the hepatic asialoglycoprotein receptor. J Med Chem (1995) 0.98
Binding of liver lipase to parenchymal and non-parenchymal rat liver cells. Biochem Biophys Res Commun (1978) 0.98
The effect of a water-soluble tris-galactoside-terminated cholesterol derivative on the fate of low density lipoproteins and liposomes. J Biol Chem (1985) 0.98
In vivo uptake of human and rat low density and high density lipoprotein by parenchymal and nonparenchymal cells from rat liver. Biochim Biophys Acta (1978) 0.97
Prostaglandin D2 mediates the stimulation of glycogenolysis in the liver by phorbol ester. Biochem J (1988) 0.97
Mechanism of glucagon stimulation of fructose-1,6-bisphosphatase in rat hepatocytes. Involvement of a low-Mr activator. FEBS Lett (1986) 0.96
New scavenger receptor-like receptors for the binding of lipopolysaccharide to liver endothelial and Kupffer cells. Infect Immun (1998) 0.96
Removal of 14 N-terminal amino acids of lactoferrin enhances its affinity for parenchymal liver cells and potentiates the inhibition of beta- very low density lipoprotein binding. J Biol Chem (1993) 0.95
Apolipoprotein E is resistant to intracellular degradation in vitro and in vivo. Evidence for retroendocytosis. J Biol Chem (2000) 0.95
Modulation of plasma protein binding and in vivo liver cell uptake of phosphorothioate oligodeoxynucleotides by cholesterol conjugation. Nucleic Acids Res (2000) 0.95
alpha3-galactosylated glycoproteins can bind to the hepatic asialoglycoprotein receptor. Eur J Biochem (2000) 0.94
Binding characteristics of scavenger receptors on liver endothelial and Kupffer cells for modified low-density lipoproteins. Biochem J (1994) 0.94
Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol (2006) 0.93
Endocytosis and breakdown of ribonuclease oligomers by sinusoidal rat liver cells in vivo. II. Effect of charge. Biochim Biophys Acta (1979) 0.93
The plasma volume of the Wistar rat in relation to the body weight. Experientia (1981) 0.92
Design and synthesis of novel amphiphilic dendritic galactosides for selective targeting of liposomes to the hepatic asialoglycoprotein receptor. J Med Chem (1999) 0.92
Lymphocyte adhesion to brain capillary endothelial cells in vitro. J Neuroimmunol (1994) 0.92
In vivo catabolism of biologically modified LDL. Arteriosclerosis (1984) 0.92
Scavenger receptor-like receptors for the binding of lipopolysaccharide and lipoteichoic acid to liver endothelial and Kupffer cells. J Endotoxin Res (2001) 0.92